Hantavirus pulmonary syndrome (also called hantavirus cardiopulmonary syndrome, HCPS) is a severe, rapidly progressive zoonotic illness caused primarily by Sin Nombre virus (SNV) in North America, transmitted via inhalation of aerosolized rodent excreta. The overall case fatality rate is approximately 35–40%, with most deaths occurring within the first 24 hours of hospital admission. [1-3] There is no specific antiviral therapy; management is entirely supportive, and early recognition is the single most important factor in survival. [3-4]
1. History
- Exposure history is critical: Ask about rodent contact, cleaning rodent-infested areas (cabins, sheds, barns, garages), rural/wilderness travel, camping, or occupational exposure (farming, forestry, military training) within the past 5–50 days (incubation period; median ~18 days) [3][5-6]
- Prodromal phase (2–7 days): Fever (100%), myalgias (100%), headache (71%), chills, malaise — notably without prominent upper respiratory symptoms (rhinorrhea, sore throat are infrequent) [3][7]
- GI symptoms are common and often misleading: Abdominal pain (can mimic acute abdomen), nausea, vomiting, diarrhea — present in ~76% [1][7]
- Cardiopulmonary phase: Sudden onset of cough, progressive dyspnea, tachycardia — can progress from room air to intubation within hours [3-4]
- Ask about geographic location: western US states carry highest risk; cases reported in 39 states [8-9]
- Seasonal pattern: peak incidence in spring and summer [4]
2. Alarm Features
- Onset of cough and dyspnea after a febrile prodrome — signals transition to the cardiopulmonary phase, which can be catastrophic within hours [3-4]
- Hypotension and tachycardia — herald cardiogenic shock; most deaths occur within 24 hours of admission [3]
- Rapidly worsening hypoxia despite supplemental oxygen
- Platelet count <40,000/μL — associated with increased mortality [3]
- Rising hematocrit (hemoconcentration) — predictive of death [7]
- Serum lactate >4.0 mmol/L or cardiac index <2.5 L/min/m² — associated with 100% mortality without ECMO [10]
- Pulseless electrical activity, VF, or VT in the setting of refractory shock [10]
3. Medications
- No approved antiviral therapy for HPS. Ribavirin showed no survival benefit in a placebo-controlled trial for HCPS. High-dose IV methylprednisolone was also ineffective [3]
- Avoid aggressive IV fluid resuscitation — exacerbates pulmonary capillary leak and non-cardiogenic pulmonary edema, increasing mortality [3-4]
- Inotropes (dobutamine, epinephrine) are the mainstay for hemodynamic support rather than volume loading [3]
- Vasopressors (norepinephrine) for refractory hypotension
- Convalescent plasma showed lower mortality in an open study with Andes virus, but is not standard of care [3]
- Favipiravir has shown efficacy in animal models when given before viremia but is not approved for clinical use [3]
4. Diet
- Not a primary management consideration in the acute setting
- NPO if intubation is anticipated or hemodynamic instability is present
- Maintain adequate hydration but with judicious fluid management — avoid fluid overload given capillary leak pathophysiology [3]
- No specific dietary triggers or long-term dietary management
5. Review of Systems
- Respiratory: Cough (initially dry), progressive dyspnea, chest tightness
- Cardiovascular: Palpitations, lightheadedness, syncope (signs of shock)
- GI: Abdominal pain, nausea, vomiting, diarrhea — present early and may dominate the prodrome [3]
- MSK: Severe myalgias, arthralgias — universal in the prodrome [7]
- Neuro: Headache, retro-ocular pain [3]
- Renal: Decreased urine output (renal involvement can overlap with HFRS features) [11]
- Skin: Petechiae (axilla, extremities) — particularly with Andes virus [3]
- Ophthalmic: Conjunctival injection [3]
6. Collateral History and Family History
- Household contacts: Determine if others in the household or travel group have similar symptoms — particularly relevant for Andes virus, which is the only hantavirus with documented person-to-person transmission (sexual contact, sleeping in same room) [3][12]
- Occupational history: farming, forestry, construction in rural areas, military field exercises [6]
- Recent cleaning of enclosed spaces (cabins, storage sheds) — classic exposure scenario
- Family history is not a major factor, though certain HLA haplotypes may influence disease severity [11]
7. Risk Factors
- Rodent exposure: Direct or indirect contact with deer mice (Peromyscus maniculatus, the SNV reservoir), or other rodent species [3]
- Rural residence — associated with increased mortality [13]
- Peridomestic rodent infestation: Cleaning rodent-contaminated areas without respiratory protection
- Outdoor activities: Camping, hiking, farming in endemic areas (western US, rural South America) [6][8]
- Seasonal: Spring/summer when rodent populations peak and human outdoor activity increases [4]
- Age >18 years and female sex — identified as prognostic factors for mortality in a systematic review [13]
- Environmental factors: drought followed by heavy rainfall increases rodent populations [8]
8. Differential Diagnosis
- Influenza / viral pneumonia — most common initial misdiagnosis; HPS distinguished by thrombocytopenia, hemoconcentration, and immunoblasts [2-3]
- Community-acquired pneumonia (atypical) — bilateral infiltrates overlap, but HPS lacks purulent sputum and toxic granulation [3]
- Sepsis with ARDS — HPS has a unique hemodynamic pattern (hypovolemia + systolic dysfunction + increased permeability) distinct from classic septic shock [14]
- Leptospirosis — similar exposure history; differentiated by jaundice, conjunctival suffusion, and renal predominance [3]
- Pneumonic plague — must consider in western US; rapid progression but with hemoptysis and gram-negative coccobacilli [3]
- Dengue / other arboviral infections — fever + thrombocytopenia overlap [3]
- Acute abdomen — GI-predominant prodrome can lead to unnecessary surgical exploration [3]
- HELLP syndrome — in pregnant women, thrombocytopenia and abdominal pain can mimic HPS [3]
9. Past Medical History
- No specific chronic illness predisposes to infection, but comorbidities may worsen outcomes
- Prior hantavirus exposure (seropositive individuals may have partial immunity)
- Immunocompromised states may alter presentation
- Pregnancy: HPS in pregnancy carries high maternal and fetal mortality
- Previous episodes of unexplained febrile illness with rodent exposure should raise suspicion
10. Physical Exam
- Vital signs: Fever, tachypnea (100%), tachycardia (94%), hypotension (50%) [7]
- Pulmonary: Bilateral crackles, signs of pulmonary edema; may be initially clear in the prodromal phase
- Cardiovascular: Mottled skin, prolonged capillary refill time — signs of low cardiac output [3]
- Abdominal: Diffuse tenderness (can mimic peritonitis) [3]
- Skin: Petechiae (axillae, extremities) — especially with Andes virus; no rash typical of SNV [3]
- Conjunctival injection [3]
- Absence of pharyngeal erythema or rhinorrhea — helps distinguish from typical URI [3]
11. Lab Studies
- CBC: Thrombocytopenia (median nadir ~64,000/μL), leukocytosis with left shift (median peak WBC ~26,000), hemoconcentration (elevated hematocrit) [3][7]
- Peripheral blood smear: Immunoblasts >10% of total leukocytes — highly characteristic; absence of toxic granulation in myeloid series [3]
- Presumptive diagnostic criteria (≥4 of 5 = 96% sensitivity, 99% specificity): thrombocytopenia, left shift, no toxic granulation, hemoconcentration, immunoblasts >10% [3]
- BMP: Mild creatinine elevation, hyponatremia [3]
- LFTs: Mild transaminase elevation, elevated LDH [3]
- Coags: Prolonged PT and PTT [7]
- Lactate: Elevated in shock; >4.0 mmol/L is ominous [10]
- Urinalysis: Proteinuria (positive quantitative proteinuria linked to mortality) [3]
- Serology: IgM antibodies (present at onset of febrile prodrome); IgG (present by end of prodrome) — confirmed by ELISA [3]
- RT-qPCR: Sensitive and specific; buffy coat preferred over plasma [3]
12. Imaging
- Chest X-ray (first-line):
- Normal during the prodromal phase
- Bilateral interstitial and alveolar infiltrates with pleural effusions develop rapidly in the cardiopulmonary phase [3-4]
- Kerley B lines and peribronchial cuffing may be seen early
- Chest CT: Bilateral septal thickening, ground-glass opacities, pleural effusions [3]
- Echocardiography: Assess cardiac index; depressed systolic function in severe cases — important for guiding inotrope therapy and ECMO decision-making [3]
- Imaging is unnecessary if the patient is in the prodromal phase with normal oxygen saturation and no respiratory symptoms
13. Special Tests
- Peripheral blood smear for immunoblasts — the single most useful rapid bedside test for presumptive diagnosis [2-3]
- Hantavirus IgM ELISA — confirmatory; send to CDC or state reference laboratory [3]
- Immunochromatographic rapid IgM assay — >90% performance compared to ELISA; useful for point-of-care in endemic areas [3]
- RT-qPCR (buffy coat) — can detect viral RNA up to 2 weeks before symptom onset [3]
- Transpulmonary thermodilution or PA catheterization — for hemodynamic monitoring in ICU (cardiac index trending) [3]
- Point-of-care ultrasound (POCUS): Lung B-lines (pulmonary edema), pleural effusions, cardiac function assessment
14. ECG
- Sinus tachycardia — most common finding
- Monitor for arrhythmias in the setting of cardiogenic shock and electrolyte derangements
- PEA, ventricular fibrillation, or ventricular tachycardia — terminal events associated with 100% mortality without ECMO [10]
- ECG is indicated in all patients with suspected HPS to establish baseline and monitor for deterioration
15. Assessment
Hantavirus pulmonary syndrome is a biphasic illness: a nonspecific febrile prodrome (mimicking influenza) followed by fulminant non-cardiogenic pulmonary edema and cardiogenic shock. The hemodynamic pattern is unique — characterized by hypovolemia, systolic dysfunction, and increased pulmonary capillary permeability — distinct from both classic cardiogenic and septic shock. [3][14] More than half of SNV infections are severe, and the cardiopulmonary phase lasts only 2–4 days, with most deaths in the first 24 hours. [3] The disease is reversible in survivors, with rapid restoration of endothelial barrier function. [3]
Severity stratification
- Mild: Prodromal symptoms only, no hypoxia, platelets >115,000 — lower risk of progression [3]
- Moderate: Hypoxia requiring supplemental O₂, bilateral infiltrates, thrombocytopenia
- Severe: Refractory shock, cardiac index <2.5, lactate >4.0, need for mechanical ventilation or ECMO [10]
16. Treatment Plan
Initial stabilization
- ABCs; early ICU admission for all suspected cases [4]
- Judicious fluid management — avoid aggressive volume resuscitation (worsens pulmonary edema) [3-4]
- Supplemental oxygen; prepare for rapid intubation
Hemodynamic support
- Dobutamine or epinephrine as first-line inotropes for low cardiac index [3]
- Norepinephrine for vasopressor support
- Avoid excessive crystalloid — inotropes preferred over volume [3]
- Consider delaying intubation until ECMO vascular access is secured, if feasible [3]
Advanced support
- Venoarterial ECMO for refractory shock or respiratory failure unresponsive to conventional therapy — 80% survival reported in one series [3][10]
- Pre-place femoral vascular sheaths early based on presumptive diagnosis [3]
- High-volume hemofiltration may serve as a bridge or alternative to ECMO in select patients [15]
No proven specific therapy
- Ribavirin: no benefit in HCPS [3]
- Corticosteroids: no benefit [3]
- Convalescent plasma: possible benefit (Andes virus data only, not standard of care) [3]
Public health
- Report all suspected cases to state/local health department and CDC [4]
- Standard precautions are sufficient for SNV (no person-to-person transmission); Andes virus requires contact/droplet precautions [12]
17. Disposition
- All suspected HPS cases require hospital admission, ideally to an ICU at a center with ECMO capability [3-4]
- Transfer early — do not wait for serologic confirmation; decisions should be based on clinical suspicion and routine labs [3]
- No patient with suspected HPS should be discharged from the ED — the transition from prodrome to cardiopulmonary phase can occur within hours [4]
- Consult critical care, infectious disease, and ECMO team early
- Notify public health authorities immediately upon clinical suspicion [4]
18. Follow Up / Return Precautions
- For the rare patient seen in the prodromal phase who is not yet admitted: return immediately for any cough, shortness of breath, chest tightness, lightheadedness, or worsening symptoms — these signal the onset of the cardiopulmonary phase [1]
- Expected recovery in survivors: Endothelial barrier function reverses quickly; most survivors recover fully, though pulmonary function may take weeks to normalize [3]
- Long-term sequelae are not well characterized; additional research is needed [3]
- Patient counseling: Educate on rodent avoidance — seal entry points in homes, use wet cleaning methods (not sweeping/vacuuming) in rodent-contaminated areas, wear N95 respirators during cleanup, ventilate enclosed spaces before entering [6]
- Household contacts of Andes virus cases should be monitored for 40 days given person-to-person transmission risk [3][12]
References
1. What Is Hantavirus?. — Abdoler EA, Malani PN. The Journal of the American Medical Association. 2025.
2. Hantavirus Pulmonary Syndrome: A Zebra Worth Knowing. — Graziano KL, Tempest B. American Family Physician. 2002.
3. Hantavirus in Humans: A Review of Clinical Aspects and Management. — Vial PA, Ferrés M, Vial C, et al. The Lancet. Infectious Diseases. 2023.
4. Hantavirus Infection in North America: A Clinical Review. — Hartline J, Mierek C, Knutson T, Kang C. The American Journal of Emergency Medicine. 2013.
5. Hantavirus. — Riquelme R. Seminars in Respiratory and Critical Care Medicine. 2021.
6. Epidemiology of Hantavirus Infections in Humans: A Comprehensive, Global Overview. — Watson DC, Sargianou M, Papa A, et al. Critical Reviews in Microbiology. 2014.
7. Hantavirus Pulmonary Syndrome: A Clinical Description of 17 Patients with a Newly Recognized Disease. — Duchin JS, Koster FT, Peters CJ, et al. The New England Journal of Medicine. 1994.
8. Hantavirus Is Associated With Open Developed Areas and Arid Climates, Highlighting Increased Risk in the Western United States. — Gorris ME, Whitesell A, Telford C, Shoemaker T, Bartlow AW. Transboundary and Emerging Diseases. 2025.
9. Hantavirus Pulmonary Syndrome: 1993-2018. — Thorp L, Fullerton L, Whitesell A, Dehority W. Pediatrics. 2023.
10. Successful Treatment of Adults With Severe Hantavirus Pulmonary Syndrome With Extracorporeal Membrane Oxygenation. — Crowley MR, Katz RW, Kessler R, et al. Critical Care Medicine. 1998.
11. The Kidney in Hantavirus Infection-Epidemiology, Virology, Pathophysiology, Clinical Presentation, Diagnosis and Management. — Koehler FC, Di Cristanziano V, Späth MR, et al. Clinical Kidney Journal. 2022.
12. “Super-Spreaders” and Person-to-Person Transmission of Andes Virus in Argentina. — Martínez VP, Di Paola N, Alonso DO, et al. The New England Journal of Medicine. 2020.
13. Prognostic Factors for Mortality in Patients Infected With New World Hantaviruses: A Systematic Review and Meta-Analysis. — Tortosa F, Ragusa MA, Neumann I, et al. BMJ Open. 2026.
14. Critical Care Management of Hantavirus Cardiopulmonary Syndrome. A Narrative Review. — Ulloa-Morrison R, Pavez N, Parra E, et al. Journal of Critical Care. 2024.
15. Targeted high volume hemofiltration could avoid extracorporeal membrane oxygenation in some patients with severe Hantavirus cardiopulmonary syndrome. — López R, Pérez-Araos R, Salazar Á, et al. Journal of Medical Virology. 2021.